Cancer Communications
indexed by SCI
BMC

doi: 10.1186/s40880-017-0244-1
Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases
Yun Wang, Yun-Fei Yuan, Hao-Cheng Lin, Bin-Kui Li, Feng-Hua Wang, Zhi-Qiang Wang, Pei-Rong Ding, Gong Chen, Xiao-Jun Wu, Zhen-Hai Lu, Zhi-Zhong Pan, De-Sen Wan, Peng Sun, Shu-Mei Yan, Rui-Hua Xu and Yu-Hong Li
Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Department of Medical Oncology, Sun Yat-sen University Cancer Center
[Abstract]

Background
Pathologic response is evaluated according to the extent of tumor regression and is used to estimate the efficacy of preoperative treatment. Several studies have reported the association between the pathologic response and clinical outcomes of colorectal cancer patients with liver metastases who underwent hepatectomy. However, to date, no data from Chinese patients have been reported. In this study, we aimed to evaluate the association between the pathologic response to pre-hepatectomy chemotherapy and prognosis in a cohort of Chinese patients.
Patients and methods
In this retrospective study, we analyzed the data of 380 liver metastases in 159 patients. The pathologic response was evaluated according to the tumor regression grade (TRG). The prognostic role of pathologic response in recurrence-free survival (RFS) and overall survival (OS) was assessed using Kaplan–Meier curves with the log-rank test and multivariate Cox models. Factors that had potential influence on pathologic response were also analyzed using multivariate logistic regression and Kruskal–Wallis/Mann–Whitney U tests.
Results
Patients whose tumors achieved pathologic response after preoperative chemotherapy had significant longer RFS and OS than patients whose tumor had no pathologic response to chemotherapy (median RFS: 9.9 vs. 6.5 months, P = 0.009; median OS: 40.7 vs. 28.1 months, P = 0.040). Multivariate logistic regression and Kruskal–Wallis/Mann–Whitney U tests showed that metastases with small diameter, metastases from the left-side primary tumors, and metastases from patients receiving long-duration chemotherapy had higher pathologic response rates than their control metastases (all P < 0.05). A decrease in the serum carcinoembryonic antigen (CEA) level after preoperative chemotherapy predicted an increased pathologic response rate (P < 0.05). Although the application of targeted therapy did not significantly influence TRG scores of all cases of metastases, the addition of cetuximab to chemotherapy resulted in a higher pathologic response rate when combined with irinotecan-based regimens rather than with oxaliplatin-based regimens.
Conclusions
We found that the evaluation of pathologic response may predict the prognosis of Chinese colorectal cancer patients with liver metastases after preoperative chemotherapy. Small tumor diameter, long-duration chemotherapy, left primary tumor, and decreased serum CEA level after chemotherapy are associated with increased pathologic response rates.
Chinese Journal of Cancer 2017, Volume: 36, Issue 11
[ PDF Full-text ]
[ Html full-text / Citation export] (BioMed Central)

[Google Scholar]


Cite this article

Yun Wang, Yun-Fei Yuan, Hao-Cheng Lin, Bin-Kui Li, Feng-Hua Wang, Zhi-Qiang Wang, Pei-Rong Ding, Gong Chen, Xiao-Jun Wu, Zhen-Hai Lu, Zhi-Zhong Pan, De-Sen Wan, Peng Sun, Shu-Mei Yan, Rui-Hua Xu and Yu-Hong Li. Pathologic response after preoperative therapy predicts prognosis of Chinese colorectal cancer patients with liver metastases. Chin J Cancer. 2017, 36:78. doi:10.1186/s40880-017-0244-1


Export citations

EndNote


SHARE THIS ARTICLE


Your Comments

  

 


Comments:


CJC Wechat 微信公众号


 

Editorial Manager


CC adopts ScholarOne Manuscripts to manage its submissions from Nov.1, 2019

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by Wiley

© Cancer Communications

651 Dongfeng Road East, Guangzhou 510060, P. R. China